Entrada Therapeutics, Inc. (TRDA) AI Dilution Summary

Entrada reported cash, cash equivalents and marketable securities of $223,005,000 at 2026-06-30, against estimated monthly burn of $10,821,000. Its funding channel is an active at-the-market program with TD Securities (USA) LLC (f/k/a Cowen and Company, LLC), authorised to $150,000,000, with $0 sold to date. The largest source of potential dilution is the S-3 shelf registration 333-291306.